Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-2: epcoritamab + R2 versus chemoimmunotherapy in previously untreated follicular lymphoma
MOH_2024-01-04_013160Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in follicular lymphoma (FL) (3 arms), sponsored by AbbVie Inc. Primary endpoint: CR30 rate. Started Dec 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2024-01-04_013160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-04_013160.